In April, the FDA granted approval to several innovative therapies, expanding treatment options across autoimmune, genetic, and oncologic conditions. Key approvals include Imaavy for generalized myasthenia gravis, Vanrafia for IgA nephropathy, and Zevaskyn, a gene therapy for recessive dystrophic epidermolysis bullosa. The agency also approved penpulimab-kcqx, a PD-1 inhibitor, for advanced nasopharyngeal carcinoma. Additionally, updated formulations of established drugs received clearance, including Atzumi, a nasal powder for acute migraine, Mezofy, an oral film formulation of aripiprazole for schizophrenia, and Jobevne, a biosimilar to Avastin (bevacizumab).